How India Exports Etanercept to the World

Etanercept, marketed as Enbrel, received FDA approval on November 2, 1998, for the treatment of moderately to severely active rheumatoid arthritis in patients unresponsive to one or more disease-modifying antirheumatic drugs (DMARDs). As a biologic, etanercept is regulated under the Biologics License Application (BLA) pathway, distinct from the Abbreviated New Drug Application (ANDA) process used for generic drugs. Consequently, there are no approved ANDAs for etanercept. The FDA's Orange Book does not list any generic equivalents for Enbrel, indicating the absence of approved biosimilars in the U.S. market.

Given the absence of approved biosimilars and the stringent regulatory requirements for biologics, the U.S. market presents limited opportunities for Indian exporters of etanercept. The complex and costly approval process for biosimilars under the BLA pathway further constrains market entry.

In the European Union, etanercept is marketed under various names, including Enbrel, which received marketing authorization on February 3, 2000. (ema.europa.eu) Biosimilar versions, such as Erelzi, have also been approved, with Erelzi receiving authorization on June 29, 2017. (ema.europa.eu) The European Medicines Agency (EMA) requires that manufacturing facilities comply with EU Good Manufacturing Practice (GMP) standards, ensuring consistent product quality and safety.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of medicinal products. Post-Brexit, the UK has established its own regulatory framework, though it remains closely aligned with EU standards. Manufacturers exporting to the UK must adhere to MHRA guidelines and may require separate marketing authorizations.

Etanercept is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in treating autoimmune conditions. The WHO Prequalification Programme does not currently list etanercept, as it primarily focuses on medicines for high-burden diseases in low- and middle-income countries. Etanercept formulations must comply with pharmacopoeial standards, including those set forth in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure quality and efficacy.

In India, etanercept is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, etanercept is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For export purposes, the Central Drugs Standard Control Organization (CDSCO) mandates a No Objection Certificate (NOC), ensuring that the exported batches meet quality standards and do not affect domestic supply.

The primary patents for etanercept have expired in major markets, leading to the development and approval of biosimilars in regions like the EU. However, in the U.S., patent litigation and regulatory complexities have delayed the entry of biosimilars, maintaining Enbrel's market exclusivity. This landscape influences the competitive dynamics and market opportunities for Indian exporters.

In February 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Fubelv, a biosimilar etanercept developed by Biosimilar Collaborations Ireland Limited, for multiple indications including rheumatoid arthritis and plaque psoriasis. (ema.europa.eu)

In January 2026, the NPPA conducted a review of biologic drug pricing, including etanercept, to assess market trends and ensure affordability. While no immediate price controls were implemented, the review indicates potential future regulatory actions.

In December 2025, the CDSCO issued revised guidelines for the export of biologics, emphasizing stringent quality control measures and documentation requirements to align with international standards.

In November 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of etanercept for the treatment of autoimmune diseases, highlighting its global therapeutic significance.

In October 2025, the EMA approved a new manufacturing site for Erelzi, a biosimilar etanercept, enhancing production capacity to meet increasing demand in the European market.

These developments reflect the dynamic regulatory and market environment surrounding etanercept, with implications for Indian exporters in terms of compliance, competition, and market access strategies.

Etanercept, a biologic medication used to treat autoimmune diseases, relies on complex manufacturing processes involving Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). India, a major producer of APIs, sources approximately 70% of its KSMs from China. This heavy reliance on Chinese imports exposes the supply chain to potential disruptions.

In recent years, environmental regulations in China have led to the shutdown of several chemical manufacturing plants, causing significant supply constraints and price volatility for KSMs. Such disruptions underscore the vulnerability of India's pharmaceutical industry to external factors affecting KSM availability.

Our proprietary trade data indicates that between 2022 and 2026, Lupin Limited dominated etanercept exports from India, accounting for 94.1% of the total export value. The top five exporters collectively held a 98.6% share, highlighting a significant supplier concentration. This high concentration poses a risk, as any operational or regulatory issues affecting these key suppliers could disrupt the global supply of etanercept.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme to boost domestic manufacturing of critical APIs and KSMs. As of March 2025, the scheme has led to an investment of ₹4,570 crore, surpassing the initial commitment of ₹3,938.5 crore. While this initiative aims to reduce dependency on imports and diversify the supplier base, its impact on etanercept's supply chain remains to be fully realized.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Geopolitical tensions in these regions have previously led to shipping delays and increased costs, affecting the timely delivery of essential medicines. Additionally, ongoing trade disputes between major economies, such as the United States and China, have introduced uncertainties in the global supply chain, potentially impacting the availability and pricing of pharmaceutical ingredients.

Regulatory agencies like the FDA and EMA have issued shortage alerts for various medications in the past, often attributing them to supply chain disruptions. While specific alerts for etanercept have not been prominent, the interconnected nature of global pharmaceutical supply chains means that disruptions in one area can have cascading effects on others.

• Diversify Supplier Base: Encourage the development of additional domestic manufacturers for etanercept to reduce reliance on a single supplier.

• Strengthen Domestic KSM Production: Invest in local production facilities for KSMs to decrease dependency on imports, particularly from China.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the sourcing and movement of raw materials and finished products.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical disruptions.

• Engage in Policy Advocacy: Collaborate with industry associations and government bodies to advocate for policies that support supply chain resilience and reduce regulatory bottlenecks.

RISK_LEVEL: MEDIUM